Potential “path forward to a cure” for genotype 2 and 3 patients
An interferon-free regimen of daclatasvir plus sofosbuvir, with or without ribavirin, cured all previously
treated hepatitis C (HCV) patients who did not respond to interferon-based triple
therapy using the approved HCV protease inhibitors boceprevir (Victrelis) or telaprevir (Incivo or Incivek), according to a report on Saturday at the 48th International Liver Congress (EASL 2013) in Amsterdam.
The advent of direct-acting antivirals has changed the
treatment paradigm for chronic hepatitis C. Yet many people with
liver disease are not in a position to wait for all-oral regimens, and
options have been proven effective for people who experience treatment
failure on the latest standard-of-care regimen consisting of pegylated
interferon, ribavirin and one of the approved
HCV NS3 protease inhibitors, boceprevir or telaprevir.